Altogether, these results show that the SRCIN1 gene is frequently, but not obligatorily, co-amplified with ERBB2 in breast cancers, arguing for a potential role of SRCIN1 as a determinant of the clinical heterogeneity of ERBB2 tumours. The gene discussed is SRCIN1; the disease is neoplasm.